MMAF-sodium-Monomethylauristatin-F-sodium-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEMMAFsodiumCat.No.:HY-15579BCASNo.:1799706-65-2Synonyms:MonomethylauristatinFsodium分?式:C??H??N?NaO?分?量:753.94作?靶點:Microtubule/Tubulin;ADCCytotoxin作?通路:CellCycle/DNADamage;Cytoskeleton;Antibody-drugConjugate/ADCRelated儲存?式:4°C,protectfromlight,storedundernitrogen*該產(chǎn)品在溶液狀態(tài)不穩(wěn)定，建議您現(xiàn)?現(xiàn)配，即刻使?。溶解性數(shù)據(jù)體外實驗DMSO:≥200mg/mL(265.27mM)*"≥"meanssoluble,butsaturationunknown.MassSolvent1mg5mg10mgConcentration制備儲備液1mM1.3264mL6.6318mL13.2637mL5mM0.2653mL1.3264mL2.6527mL10mM0.1326mL0.6632mL1.3264mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液；該產(chǎn)品在溶液狀態(tài)不穩(wěn)定，建議您現(xiàn)?現(xiàn)配，即刻使?.體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實驗的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥5mg/mL(6.63mM);Clearsolution1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE2.請依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥5mg/mL(6.63mM);Clearsolution3.請依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥5mg/mL(6.63mM);ClearsolutionBIOLOGICALACTIVITY?物活性MMAFsodium(MonomethylauristatinFsodium)?種有效的微管蛋?聚合(tubulinpolymerization)抑制劑，?作抗腫瘤藥物。MMAFsodium(MonomethylauristatinFsodium)?泛?作抗體偶聯(lián)藥物(ADCs)的細(xì)胞毒性成分，如Vorsetuzumabmafodotin和SGN-CD19A。IC50&TargetAuristatin體外研究MMAFinhibitsanaplasticlargecelllymphomaKarpas299,breastcarcinomaH3396,renalcellcarcinoma786-OandCaki-1cellswithIC50sof119,105,257and200nMinvitrocytotoxicityassay[4].戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?JControlRelease.2018May10;277:48-56.?MolTherNucleicAcids.2018Mar2;10:227-236.?TargetOncol.2019Oct;14(5):577-590.?OncolRep.2020Dec9.?UniversityofMinnesota.2022Sep.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].DoroninaSO,etal.EnhancedactivityofmonomethylauristatinFthroughmonoclonalantibodydelivery:effectsoflinkertechnologyonefficacyandtoxicity.BioconjugChem.2006Jan-Feb;17(1):114-24.[2].LeeJW,etal.EphA2targetedchemotherapyusinganantibodydrugconjugateinendometrialcarcinoma.ClinCancerRes.2010May1;16(9):2562-70.[3].LeeJJ,etal.Enzymaticprenylationandoximeligationforthesynthesisofstableandhomogeneousprotein-drugconjugatesfortargetedtherapy.AngewChemIntEdEngl.2015Oct5;54(41):12020-4.[4].KimEG,etal.StrategiesandAdvancementinAntibody-DrugConjugateOptimizationforTargetedCancerTherapeutics.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplicatio